cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib

Paul G. Kluetz, MD

PASSION Results Support Further Study of Camrelizumab Plus Apatinib in SCLC

Multidisciplinary Tumor Boards: Approaches Across Different Institutions

Shirish Gadgeel, MD

Prior Pneumonitis as a Risk Factor for Treatment-Associated Pneumonitis With Immune Checkpoint Inhibitor Therapy

Karen L. Reckamp, MD, MS

Gideon Blumenthal, MD

David LeDuc

Multidisciplinary Tumor Board: A Single Institution’s Perspective

Tobacco Use Assessment and Cessation Support: More Important Now Than Ever

Single-Agent Pembrolizumab Active Against STK11- and KEAP1- Mutated NSCLC According to KEYNOTE-042 Analysis